Partners

Consistent with our strategy, ChemoCentryx seeks to balance internal product development programs with the partnering of select compounds to leading pharmaceutical partners. We intend to retain significant rights to those therapeutic programs which address specialty market opportunities and partner those programs that address primary care markets. Working closely with our partners, we bring several fundamental assets and strengths, including our unparalleled expertise in the field of chemokine biology and chemokine-based drug discovery and clinical development.

For more information about ChemoCentryx partnering opportunities, please contact: busdev@chemocentryx.com

Our Strategic Alliance with GlaxoSmithKline

In August 2006, we entered into a strategic alliance with Glaxo Group, Ltd., or GSK, an affiliate of GlaxoSmithKline. Under the terms of the agreement, we are responsible for the discovery and development of small molecule antagonists targeting four defined chemokine and chemo-attractant receptor targets through clinical proof-of-concept, at which point GSK will have exclusive options to license up to six product candidates (and their associated backup compounds) for further development and commercialization on a worldwide basis.

The agreement encompasses Traficet-EN, a specific CCR9 antagonist which has been studied in our PROTECT-1 clinical trial of greater than 400 patients with moderate-to-severe Crohn's disease. GSK has exercised its option to obtain an exclusive license for further development and worldwide commercialization of Traficet-EN. Under the terms of the agreement, ChemoCentryx has received an option exercise fee and is eligible for further regulatory and sales milestone payments. Following successful development and commercialization of the product candidate ChemoCentryx will also receive double-digit royalties on product sales with the ability to increase royalties by co-funding development through Phase III clinical trials and co-promoting to physician specialists in the United States. Besides Traficet-EN, the agreement also includes small molecule programs targeting chemokine receptor CCR1, the chemo-attractant receptor C5a and a fourth selected chemo-attractant receptor.

Our proprietary programs around CCR2, CXCR7 or any other receptors are not part of the GSK collaboration.

^ Return to Top